Gene
PAPPA2
pappalysin 2
Explore in graph →CI-GENE-00018877HGNC:14615 ENSG00000116183 NCBI 60676 CIViC Cancer geneApproved
Curated evidence
Clinical evidence (1)
CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25765070
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PAPPA2 Y1520X1 | ||||||||
| Pembrolizumab | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4774In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with PAPPA2 Y1520* nonsense mutation, treated with pembrolizumab monotherapy, was associated with a 4 … (full text at CIViC) PMID 25765070 · Rizvi et al., 2015 · Open in CIViC | civic |
Cohorts
Alteration frequency by cohort (103)
Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.
gdcProvenance
- Source
- NCI Genomic Data Commons (open aggregated data)
- Dataset
- GDC top mutated genes by project
- Version
- Data Release 46.0
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- cohort
- License
- Open-access GDC data (NCI); citation of GDC and originating program requested
- Run
- ING-GDC-20260908-000001
| Cohort | Mapped cancer | Alteration | Affected (n) | Profiled (n) | Frequency (%) | Rank in cohort | Source |
|---|---|---|---|---|---|---|---|
| Lung Adenocarcinoma TCGA-LUAD | Lung Adenocarcinoma | Ssm |
Literature
Linked publications (0)
Data not yet available
No publication linked to this gene yet.